A breakthrough therapy to treat certain advanced blood cancers, known as chimeric antigen receptor T-cell therapy, has shown promising results — even complete remissions in some patients — but its costs aren't sustainable for hospitals, which stand to lose hundreds of thousands of dollars per treatment, according to a commentary published in the Journal of Clinical Oncology.
The authors were: Chrisopher Manz, MD, a fellow in the division of hematology Oncology at the Philadelphia-based University of Pennsylvania, David Porter, MD, a professor of leukemia care at the University of Pennsylvania; and Justin Bekelman, MD, associate professor of radiation oncology at the University of Pennsylvania.